Ibuprofen - Oxford Pharmascience
Alternative Names: Ibuprofen oral suspension - Oxford Pharmascience; Ibuprofen-layered double hydroxide; Ibuprofen-LDH; OXP 001; OXP 002; OXProfen; OXPzero™ Ibuprofen;… See moreLatest Information Update: 07 Jan 2022
Price :
$50 *
At a glance
- Originator Oxford Pharmascience
- Class Amines; Analgesics; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Musculoskeletal pain
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Musculoskeletal-pain in United Kingdom (PO, Tablet)
- 27 Feb 2018 Ibuprofen is still in phase I trials for Musculoskeletal pain in UK
- 27 Sep 2017 Suspended - Phase-I for Musculoskeletal pain in United Kingdom, pending conclusion of a strategic review (PO)